【word】 CATT研究:兰尼单抗与贝伐珠单抗的“判决书”
CATT研究:兰尼单抗与贝伐珠单抗的“判
决书”
脂质体肺部给药的应用进展
【8】VyasSP,KannanME,JainSY,eta1.Designoflipo—
somalaerosolsforimproveddeliveryofrifampicinto
alveolarmacrophage~-J]./ntJ2004_,269(137—49.
[9】LeJ,SchillerDS.AerosolizedDeliveryofAntifungal
Agents[J].CurrFungalInfectRep,2010,4(2):96102.
【10】VyasSP,QuraishiS,GuptaS,eta1.Aerosolizedlipo—
some—baseddeliveryofamphotericinBtoalveolar
macrophages[J]./ntJnr,n,2005,296(1—21:12—25.
【11】BriscoeP,CaniggiaI,GravesA,eta1.Deliveryof
superoxidedismutasetopulmonaryepitheliumviapH-
sensitiveliposomes[J].AmJPhysiol,1995,2680):L374-
8
【12】WijagkanalanW,KawakamiS,HiguchiY,eta1.In—
tratraeheallyinstilledmannosylatedcationicliposome/
NFKBdecoycomplexesforeffectivepreventionof
LPS-inducedlunginflammationJControlledRelease,
2010,ArticleinPress,CorrectedProof.
[13JShahSP,MisraA.LiposomalAmikacinDryPowder
InhMenEfieetofFinesonInVitroPerformancelJ1.
AAPSPharmSciTech,2004,5(4):e65.
【14】OkusanyaOO,BhavnaniSM,HammelJ,eta1.Phar-
maeokineticandPharmacodynamicEvaluationofLipo—
somalAmikacinforInhaLationinCysticFibrosisPa—
tientswithChronicPseudomonalInfection【JlAntimicrob
AgentsChemother,2009Sep,53(9):384754.
[151ShahiwalaA,MisraA.APreliminaryPharmacokinetic
StudyofLiposomalLeuprolideDryPowderInhaler:A
TechnicalNoteAAPSPharmSciTech,2005,6
E482-6.
[16】BaiS,GuptaV,AhsanF.Cationicliposomesascar—
riersforaerosolizedformulationsofananionicdrug:
Safetyandefficacystudy[J].EurJmSci.2009.38
f21:165—71.
[17]AudouySA,deLeijLF,HoekstraD.Invivocharac—
teristicsofcationicliposomesasdeliveryvectorsfor
genetherapy[J].Res,2002,19(II):1599—605.
[18】张莉,景年水,李云霞,等.脂质体肺部给药的研究
进展[J1.中国医院药学杂志,2008.28(17):1496—8.
[19】DokkaS,ToledoD,ShiX,eta1.Oxygenradical—me—
diatedpulmonarytoxicityinducedbysoniccationicli—
posomes[J].PharmRes,2000,l7(5):52l一5.
[20】CryanSA.Carrier—basedStrategiesfi)rTargetingPro—
teinandPeptideDrugstotheLungs[J1.AA2005,
7f11:E20—41.
ApplicationandDevelopmentofLiposomeFormulationinPulmonaryDelivery
WANGYan,TANGYue,LUXi-~ng,ZHUJia-bi
SchoolofPharmacy,ChinaPharmaceuticalUniversity,Nanjing21000~China
ABSTRACTTheliposome—mediatedpulmonarydrugdeliveryasanon—i
nvasiveadministration.makes
drugslocatedatthesiteofactiontotreatpulmonarydiseasesdirectly.reducesextrapulmonaryside—effects
avoidsthehepaticfirstpasseffect,increasesthebioavailabilityandavoidsfrequentadministrationasthe
double—layeroftheliposomecanincreasetheretention—time.Therelateda
dvantageoftheliposome—
mediatedpulmonarydrugdeliveryandthewayofadministrationaremainlyintroducedinthisreview.We
alsosummarizedtheresearchanddevelopmentoftherelevantliposomesathomeandabroad.beingused
toworkthroughpulmonarypathway,asthecarriersofantiinflammatoryanda
nti-infectivedrugs,
antioxidants,antasthmatics,antitumordrugs,antithromboticsandsoon.
KEYWORDSLiposome;Pulmonarydelivery;Carrier;Nebulize;Neinhale;
Safety
近5年来,患者和临床医生在两种治疗新生血管性
老年黄斑变性(AMD)药物的选择上一直纠结不清.AMD
主要由黄斑内血管的异常增生和渗漏所引起.抗血管内
皮生长因子(WGF)重复注入眼内可抑制VEGF活性,进
而可在大多数患者中预防失明.
贝伐珠单抗和兰尼单抗为两种最常用的抗VEGF药
物,前者被FDA批准用于治疗某些癌症,后者则被批准
用于治疗眼部疾病.由于两种药物存在治疗费用差异(前
者每剂仅需50美元,后者则需2000美元)和临床疗效相
似性,贝伐珠单抗在缺少I类证据的情况下仍被广泛使用.
为了进?步明确两者对澌生血管性AMD的治疗效果,
美国国家卫生研究院(NIH)资助了一项关于上述两种药物
治疗
的大规模临床研究(CATT),研究结果4月28日
在线发
于《新英格兰医学杂志.研究表明,1年时贝伐殊单
抗和兰尼单抗对AMD患者视辙度改善效果相等.
美国迈阿密大学米勒医学院罗斯菲尔德(Rosenfeld)
博士在同期述评中亦明确指出,CATT研究结果以及全球
总体经验支持贝伐珠单抗或兰尼单抗用于治疗新生血管
性AMD.目前需要对应用兰尼单抗高额费用的正当性加
以明确.作为兰尼单抗的替代药物,廉价有效的贝伐珠单
抗应继续在全球范围内应用.
(来源:中国医学论坛报2011-06-07)